Physician profile
Vignesh Raghunath
NPI 1639580475
$3,696.56
in general payments reported to CMS, 2019-2025
25 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.37 · 2021: $867 · 2022: $548 · 2023: $255 · 2024: $631 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,230 · Entertainment: $15.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,230.33 |
| Entertainment | $15.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $516.39 | 2021-2025 | Lifevest |
| Pfizer INC. | $407.26 | 2021-2025 | |
| Abbott Laboratories | $383.31 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $358.53 | 2025 | |
| Glaxosmithkline, LLC. | $353.39 | 2024-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Amgen INC. | $279.59 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $193.37 | 2021-2025 | Farxiga, Lokelma |
| Astellas Pharma US INC | $189.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.56 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $150.43 | 2021-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $147.92 | 2024-2025 | Wegovy |
| Optinose US, INC. | $102.07 | 2024-2025 | |
| Baxter Healthcare | $88.77 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Monarch Airway Clearance System |
| Abiomed | $58.80 | 2023-2025 | Impella |
| Merck Sharp & Dohme LLC | $49.16 | 2022-2025 | Verquvo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $46.29 | 2025 | Zepbound, Mounjaro |
| Chiesi USA, INC. | $39.00 | 2022-2025 | Juxtapid |
| Kiniksa Pharmaceuticals International, Plc | $32.19 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $26.16 | 2022 | |
| Edwards Lifesciences Corporation | $21.23 | 2020 | |
| Impulse Dynamics (USA) INC. | $20.74 | 2022 | |
| Harmony Biosciences LLC | $16.07 | 2025 | |
| Opsens INC. | $15.33 | 2023 | Optowire |
| United Therapeutics Corporation | $14.88 | 2021 | |
| Medivance, INC. | $14.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vignesh Raghunath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.